MapLight Therapeutics (MPLT) CEO granted new RSUs and options in 2026 filing

Rhea-AI Filing Summary

MapLight Therapeutics reported that Chief Executive Officer and director Christopher A. Kroeger received new equity awards. On February 5, 2026, he was granted 23,145 restricted stock units, each representing one share of voting common stock, at a price of $0. After this grant, he directly beneficially owned 1,649,751 shares of voting common stock.

On the same date, Kroeger also received an option to buy 93,955 shares of voting common stock at an exercise price of $15.70 per share, with vesting beginning in 2027. In addition, 101,190 shares of voting common stock are held indirectly through the C&M Kroeger Nominee Trust, where he and his spouse serve as co‑trustees with voting and dispositive power.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kroeger Christopher A.

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	02/05/2026		A		23,145(1)	A	$0(2)	1,649,751	D
Voting Common Stock								101,190	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$15.7	02/05/2026		A		93,955		(4)	02/04/2036	Voting Common Stock	93,955	$0	93,955	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date.

2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.

3. The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.

4. 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MPLT CEO Christopher Kroeger report on February 5, 2026?

Christopher Kroeger reported grants of RSUs and stock options. He received 23,145 restricted stock units at $0 and an option for 93,955 shares at a $15.70 exercise price, both tied to continued service and future vesting schedules.

How many MapLight Therapeutics (MPLT) shares does the CEO directly own after these grants?

After the reported RSU grant, the CEO directly owns 1,649,751 shares. This figure reflects his beneficial ownership of voting common stock in his own name, separate from any indirect holdings through trusts or other entities.

What are the vesting terms of Christopher Kroeger’s RSU award at MapLight Therapeutics (MPLT)?

The RSU award vests over multiple years. One quarter vests on January 1, 2027, and one sixteenth vests on each following April 1, July 1, October 1, and January 1, contingent on his continued service with the company.

What are the key details of the stock option granted to the MPLT CEO?

The CEO received an option for 93,955 shares at $15.70 per share. One quarter vests on February 5, 2027, and one forty‑eighth vests monthly thereafter, with an expiration date of February 4, 2036, subject to continued service.

Does Christopher Kroeger have any indirect ownership of MapLight Therapeutics (MPLT) shares?

Kroeger indirectly holds 101,190 shares via the C&M Kroeger Nominee Trust. He and his spouse are co‑trustees of this trust and have both voting power and dispositive power over those voting common stock shares.

Do the reported RSUs for MPLT’s CEO deliver actual shares immediately?

No, the RSUs represent contingent rights to receive shares later. Each restricted stock unit corresponds to one share of voting common stock, which is delivered only as the units vest under the stated service‑based schedule.